NCT01587703 - A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers | Biotech Hunter

Enrollment

196

Participants

Timeline

Start Date

March 28, 2012

Primary Completion Date

April 13, 2018

Study Completion Date

July 29, 2019

Conditions

Carcinoma, Midline

Interventions

DRUG

GSK525762

Begin at Dose Level 1 and increase up to 2 fold

Trial Locations (17)

3168

GSK Investigational Site, Clayton

19104

GSK Investigational Site, Philadelphia

28040

GSK Investigational Site, Madrid

29010

GSK Investigational Site, Málaga

33076

GSK Investigational Site, Bordeaux

37232

GSK Investigational Site, Nashville

69373

GSK Investigational Site, Lyon

75248

GSK Investigational Site, Paris

77030

GSK Investigational Site, Houston

21231-2410

GSK Investigational Site, Baltimore

02215

GSK Investigational Site, Boston

1066 CX

GSK Investigational Site, Amsterdam

03080

GSK Investigational Site, Seoul

03722

GSK Investigational Site, Seoul

08035

GSK Investigational Site, Barcelona

SM2 5PT

GSK Investigational Site, Sutton

NE7 7DN

GSK Investigational Site, Newcastle upon Tyne